MBX MBX Biosciences, Inc. Common Stock
Healthcare$31.75-0.31%ClosedMarket Cap: $1.07B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.39
P/S
0.00
EV/EBITDA
-10.65
DCF Value
$2.02
FCF Yield
-7.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.5%
ROA
-19.1%
ROIC
-22.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-27.3M | $-23.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-25.8M | $-22.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-98.1M | $-87.0M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-23.9M | $-21.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-21.8M | $-19.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-26.5M | $-23.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-18.6M | $-15.6M | $— | — |
| FY null | $0.00 | NaN% | $-68.2M | $-61.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-19.6M | $-18.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-16.7M | $-15.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-13.3M | $-12.3M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-10.0M | $-8.8M | $-0.28 | — |